JNJ
Another analyst, another little raise
Wells Fargo hopped on the Johnson & Johnson train and bumped its price target to $263 from $240 while keeping an Overweight rating. Translation: the bank still thinks J&J has room to climb, even after the stock has already been acting like the responsible adult in the health-care aisle.
Why you should care
This is not some moonshot biotech bet. It’s more like Wall Street saying, “Yeah, the giant diversified healthcare conglomerate still looks annoyingly solid.” And in a market that loves drama, steady cash flows and a raised target can still matter.
The backdrop is doing the heavy lifting
The call lands right after a flurry of J&J-related updates, including its Q1 results and a fresh 2026 outlook. So this isn’t happening in a vacuum — analysts are effectively re-checking the math after management showed the business can keep growing while some legacy pieces, like Stelara, keep acting like the one cousin who never leaves the group chat.
Big picture
A higher price target doesn’t guarantee a breakout, but it does reinforce the narrative that J&J is still a defensive heavyweight with some upside left. If you own it, this is more “quiet confidence” than fireworks — which, honestly, is pretty on-brand for J&J.